| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0006 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.17 | 0.0006 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.001 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |